Bisphosphonate use before Primary THA May Elevate Risk of Periprosthetic Hip Fracture
Bisphosphonates are a group of drugs that work by slowing bone resorption by reducing osteoclast function. Many studies have shown that this class of medication can improve bone density and reduce the risk of fracture in patients with a reduced bone density. Bisphosphonates can be taken orally through intravenous infusion.
In patients with osteoporosis, the use of bisphosphonates before undergoing primary total hip arthroplasty is an independent risk factor for periprosthetic fractures, says Dr Serino and colleagues in the study “Bisphosphonate Use may be Associated with an Increased Risk of Periprosthetic Hip Fracture.”
Osteoporosis is prevalent in patients undergoing primary total hip arthroplasty (THA).
Researchers evaluated the bisphosphonate effect in treating osteoporotic patients undergoing primary THA using a database of 30,137 patients.
These patients had osteoporosis before primary, elective THA (2010 – 2020). The exclusion criteria included patients undergoing non-elective THA and using corticosteroids/ medications for osteoporosis.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.